Onkológia 1/2024
The role of osimertinib in the treatment of lung cancer
Osimertinib is a third-generation oral, selective, irreversibly acting tyrosine kinase inhibitor. It is effective not only against activating EGFR gene mutations but also against the resistant T790M mutation. By its efficacy in a wide range of indications, it shows superiority to EGFR TKIs of lower generations. Also unforgettable is its low toxicity and the highest activity in the central nervous system (CNS). In the review article, I present the basic characteristics of the drug with a mechanism of action, as well as clinical studies demonstrating its irreplacable use in the treatment of EGFR mutated lung cancer.
Keywords: non small lung carcinoma, EGFR mutation, T790M mutation, tyrosin kinase inhibitors, osimertinib, progression free survival
